Ir para o conteúdo principal

Spero Therapeutics (NASDAQ: SPRO) — Perfil da empresa, notícias e dados financeiros

Logo de Spero Therapeutics
SPRO Spero Therapeutics
Spero Therapeutics primary media
Perfil da empresa

Spero Therapeutics

Spero Therapeutics (NASDAQ:SPRO) focuses on developing treatments for multi-drug resistant bacterial infections. With a robust pipeline primarily targeting the most critical and hard-to-treat bacterial infections, Spero is committed to innovating within the field of antibiotic development. The company's projects span across various stages of clinical development, aiming to address the growing global threat of antimicrobial resistance. One of their key objectives includes advancing their lead candidates through clinical trials to bring novel therapies to patients in need, while also exploring potential in antibacterial and diagnostic products to broaden their impact on public health. Spero Therapeutics is driven by a mission to save lives by revitalizing the arsenal against bacterial infections.

Resumo

Public USParticipação acionária
2013Ano de fundação
46Funcionários
Massachusetts, United StatesSede
Carregando mapa...
Presença global

Operações

Todos os locais
United States

Produtos e/ou serviços de Spero Therapeutics

  • "SPR206, an IV-administered agent aimed at combating multidrug-resistant Gram-negative bacteria"
  • "SPR720, an oral therapy for non-tuberculous mycobacterial (NTM) infections"
  • "Potentiator platform, enhancing the performance of existing antibiotics against resistant bacteria"
  • "SPR994, an oral formulation of tebipenem, targeting complicated urinary tract infections (cUTI)"
  • "Collaborations with government and industry partners to develop and commercialize novel antimicrobial agents"

equipe executiva do Spero Therapeutics

  • Esther P. RajaveluCEO, President, CFO, Chief Business Officer, Treasurer & Director
  • Timothy KeutzerChief Operating Officer
  • John RaymondSenior Vice President of Finance & Business Operations
  • Debra Jeske ZackChief Medical Officer
  • Sheila FinanSenior VP & Controller

Principais indicadores financeiros

Resultados divulgados pela Spero Therapeutics, em USD.

Cap. de mercado
68,1 mi
Receita (TTM)
47 mi
P/L
8.4
LPA (diluído, TTM)
0.1
Dividend yield
—
Margem de lucro
15.7%
Receita e lucro anuais da Spero Therapeutics
Fim do ano fiscalReceitaResultado operacionalLucro líquido
59,6 mi-24 mil8,6 mi
48 mi-73,4 mi-68,6 mi
103,8 mi21,5 mi22,8 mi
48,6 mi-42,2 mi-46,4 mi